Clinical trials: Pneumonia in Children
SARS-CoV-2 Infection, COVID-19
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and…
- Trial name
- NCT04816643
- Testing
- Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg
- Where
- 128 sites in United States, Brazil and 4 more
- Volunteers
- 11,837 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an…
- Trial name
- NCT04796896
- Testing
- mRNA-1273, mRNA-1273.214
- Where
- 91 sites in United States, Canada
- Volunteers
- 11,942 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Syncytial Virus Infections
A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
The purpose of the study is to learn about the safety and amount of sisunatovir in the blood of infants and children up to age 60 months.
- Trial name
- NCT06102174
- Testing
- Active
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 10 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
In order to verify the clinical value and safety of Xiyanping injection in children with CAP, we intend to carry out this multi-center, large-sample, non-intervention clinical research through more rigorous and scientific design.
- Trial name
- NCT04158310
- Volunteers
- 9,207 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Pneumonia, Bronchiolitis
Diagnosing Respiratory Disease in Children Using Cough Sounds
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in diagnosis of pneumonia and other respiratory conditions (bronchiolitis, asthma/reactive airway disease, croup, upper or…
- Conditions
- Pneumonia, Bronchiolitis, Asthma, Croup
- Trial name
- SMARTCOUGH-C (NCT02973282)
- Testing
- Recording of Infants and Children's Cough Sounds
- Where
- 3 sites in United States
- Volunteers
- 1,245 people
- Sponsor
- ResApp Health Limited
COVID-19
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
This study is a randomized and controlled phase Ⅳ clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04993365
- Testing
- Experimental Group, Control Group
- Where
- 2 sites in China
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
SARS-CoV-2 Infection
COVID-19 Paediatric VLA2001-321 Study
This is a Randomized, Double-blinded, Active-controlled Study to evaluate the Safety, Tolerability and Immunogenicity of VLA2001 in participants of ≥2 to 12 years.
- Trial name
- NCT05298644
- Testing
- VLA2001, Active Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Pneumonia
Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia
The primary objective is to assess the safety of telithromycin (HMR3647) 20 mg/kg qd for 5-7 days in children with community-acquired pneumonia (CAP).
- Trial name
- NCT00638859
- Testing
- Telithromycin (HMR3647)
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Sanofi
COVID-19
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination…
- Trial name
- NCT05193279
- Testing
- Candidate vaccine, SCB-2019
- Where
- 2 sites in Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT00914888
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
COVID-19
Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years
This was a non-randomized, three-armed, open-label, parallel-group, non-inferiority trial designed to compare the immunogenicity and safety of the SpikoGen COVID-19 vaccine in children aged 5 to <12 years and 12 to <18 years with…
- Trial name
- NCT05231590
- Testing
- Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Cinnagen
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children.
- Conditions
- SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
- Trial name
- NCT05543616
- Testing
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
- Where
- 96 sites in United States, Brazil and 3 more
- Volunteers
- 4,338 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Infections, Streptococcal
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ given at 12-18 mo of age to children primed with either…
- Trial name
- NCT00370396
- Testing
- Synflorix, Prevenar, Infanrix hexa
- Where
- 35 sites in Finland, France and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents
This study is a randomized, double-blinded, placebo-controlled, phase Ⅱb clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co.
- Trial name
- NCT04884685
- Testing
- SARS-CoV-2 Inactivated Vaccine
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID-19
A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children
The purpose of this clinical trial is to learn about the safety and immune responses of the study vaccine (called a bivalent BNT162b2 Omicron containing vaccine) in healthy infants and children.
- Trial name
- NCT05630352
- Testing
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
- Volunteers
- healthy volunteers welcome
- Sponsor
- BioNTech SE
Community-acquired Bacterial Pneumonia
Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia
This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).
- Trial name
- NCT02605122
- Testing
- Solithromycin, Standard of Care
- Where
- 58 sites in United States, Bulgaria and 4 more
- Volunteers
- 97 people
- Sponsor
- Melinta Therapeutics, Inc.
COVID-19
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart…
- Trial name
- COVID-19 (NCT05468736)
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
- Where
- 94 sites in United States, Colombia and 8 more
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Novavax
Pneumonia, Pneumonia in Children
Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia
The main questions this study aims to answer are: Does using probiotic nasal spray (LiveSpo Navax containing Bacillus subtilis and Bacillus clausii, 1x10^9 CFU/mL), with or without oral probiotics (LiveSpo Pregmom containing…
- Trial name
- NCT07399717
- Testing
- Navax, Navax-PregMom
- Where
- Vietnam
- Volunteers
- 330 people
- Sponsor
- Anabio R&D
Pneumococcal Disease
Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan
Streptococcus pneumoniae is a major cause of pneumonia, among infants and children in Japan and worldwideThis study plans to investigate the rate of invasive pneumococcal disease "IPD " and the rate of hospitalizations due to…
- Trial name
- NCT00757575
- Where
- 2 sites in Japan
- Volunteers
- 28,511 people
- Sponsor
- Pfizer